CA-PERSONALIS
20.5.2019 09:07:07 CEST | Business Wire | Press release
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST.
The presentation , entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT ™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy.
ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.
The presentation will be delivered by Robert Power, MS, Global Product Manager for Personalis.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA ’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005195/en/
Contact:
Jennifer Havlek pr@personalis.com www.personalis.com 650-752-1300
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arrow Electronics lancerer en ny forretning, Capstone, for at øge fokus på IP&E-løsninger9.11.2026 07:00:00 CET | Pressemeddelelse
Arrow præsenterer den nye forretning på electronica-messen i München (10.-13. nov) Arrow Electronics, Inc. (NYSE:ARW) annoncerede i dag lanceringen af Capstone, en global forretning dedikeret til interconnect, passiver og elektromekaniske (IP&E) produkter, løsninger og services. Med Capstone skaber Arrow en fokuseret og specialiseret go-to-market-tilgang for IP&E idet det teknologisegment bliver mere kritisk for systemets ydeevne, pålidelighed og forsynings sikkerhed. Capstone er designet til at gøre IP&E nem at specificere, indkøbe og skalere. Kunder vil få fordelen ved dedikeret IP&E ressourcer, hurtig beslutningstagning og bred teknisk viden, både på on-board og off-board produkter. Med et fokuseret brand kan Capstone tilbyde kunderne mere målrettet rådgivning og støtte gennem hele processen – fra de første designovervejelser til den færdige produktion. Det giver kunderne et bedre grundlag for at træffe de rigtige beslutninger, mindske risikoen undervejs og skabe de bedste skalerbar
Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe9.11.2026 07:00:00 CET | Press release
Zemcelpro is authorised in the European Union for eligible adults with blood cancers who need an allogeneic stem cell transplant and have no other suitable donor cells available. Avanzanite secures exclusive commercialisation rights to Zemcelpro across 32 countries covering the European Economic Area, UK and Switzerland including potential indication expansion. Avanzanite will become the EU marketing authorisation holder following regulatory transfer and support a planned Phase 3 trial. Zemcelpro becomes Avanzanite’s fifth rare disease launch and first advanced therapy medicinal product (ATMP). Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commissi
GigaDevice to Showcase Intelligent Embedded Solutions at electronica 20269.11.2026 07:00:00 CET | Press release
Experience Intelligent Motion Through Real-World Applications in Robotics, Industrial, Automotive, and Computing GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will showcase its latest embedded technologies and application-oriented solutions at electronica 2026. As the company continues to strengthen its presence in Europe, the exhibition provides an opportunity to engage with regional customers and partners and demonstrate solutions addressing evolving needs across industrial automation, automotive electronics, and intelligent computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261108191898/en/ Experience Intelligent Motion at Electronica Munich “Europe is an important market for GigaDevice, with strong demand for innovation across industrial automation and automotive electronics,” said Dr. Reiner Jumpertz, Vice President and Gene
Sceye og SoftBank Corp. indgår aftale om en flåde af stratosfæriske platforme, der skal sikre dækning i hele Japan9.11.2026 02:38:00 CET | Pressemeddelelse
Den femårige aftale bygger videre på Sceyes vellykkede test af stratosfærisk forbindelse i Japan og tager et skridt nærmere fuld udrulning af HAPS som stratosfærisk infrastruktur og som en hjørnesten i SoftBanks strategi om et allestedsnærværende netværk Sceye, en amerikansk virksomhed inden for rumfart og materialeteknologi, der udvikler højtflyvende platformssystemer (HAPS) til infrastruktur i stratosfæren, annoncerede i dag en femårig rammeaftale (MSA) med SoftBank Corp. (TOKYO:9434, "SoftBank") om at fremstille, opsende og drive en flåde af Sceyes HAPS-platforme over Japan med det mål at opnå dækning i hele landet. Aftalen videreudvikler virksomhedernes partnerskab fra demonstrationsflyvninger til fuldt udbygget infrastruktur i stratosfæren. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261103165280/da/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan
COP31: World Cannot Afford Another Decade of Fossil Fuel Dependence as Climate Crisis Deepens8.11.2026 06:05:00 CET | Press release
350.org calls on governments gathering at UN climate talks in Türkiye to turn promises into action, make polluters pay and deliver a just transition away from fossil fuels As world leaders prepare to gather in Antalya for COP31, 350.org is warning that the world cannot afford another decade of delay in transitioning away from fossil fuels. The UN climate conference starts amidst the largest fossil fuel crisis in history and people all over the world are facing increasingly devastating climate impacts while fossil fuel companies continue to rank obscene profits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261107414423/en/ Ahead of COP31, 350 Türkiye raised a “Climate Justice, Now” banner at Antalya’s Kaleiçi Harbor, urging world leaders to commit to a just transition away from fossil fuels. Photo credit: Caner Özkan / 350.org 350.org is calling on the Turkish and Australian COP31 presidencies to build on this momentum and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom